Valion Bio's Velocity Bioworks Secures Exclusive License for Next-Generation NMR Diagnostic Platform
核心洞察
Velocity Bioworks (搜索), a subsidiary of clinical-stage immunotherapeutics company Valion Bio (搜索), has secured exclusive commercial rights to LarmorBio (搜索)'s BioScan-NMR (搜索)™ platform, a next-generation nuclear magnetic resonance system for rapid, label-free biological sample analysis.
The first commercial installation is targeted for July 2026 at Velocity Bioworks (搜索)' San Antonio facility, positioning the company as a strategic reference site for the advanced diagnostic technology.
The agreement establishes a co-dependent partnership structure rather than a traditional vendor-customer relationship, with both companies aligned on validation, optimization, and scaled deployment of the platform.
Valion Bio (搜索), Inc. (Nasdaq: VBIO), a clinical-stage immunotherapeutics company, announced that its wholly owned subsidiary Velocity Bioworks (搜索) has entered into an exclusive commercial development and license agreement with LarmorBio (搜索), Inc. for the BioScan-NMR (搜索)™ platform, a next-generation nuclear magnetic resonance (NMR) system. The agreement positions Velocity Bioworks to host the first commercial deployment of this advanced diagnostic technology, with installation and commissioning at the company's San Antonio facility targeted for July 2026.
Strategic Partnership Structure
Valion Bio (搜索) secured the exclusive license and reference site arrangement at pre-institutional pricing, ahead of LarmorBio (搜索)'s pending Series A financing. The structure establishes the two companies as co-dependent strategic partners rather than in a conventional vendor-customer relationship, with both parties commercially and operationally aligned on the validation, optimization, and scaled deployment of the BioScan-NMR (搜索) platform.
"Securing exclusive commercial rights to BioScan-NMR (搜索) ahead of LarmorBio (搜索)'s Series A reflects how we are building Velocity Bioworks (搜索) — early access to differentiated technologies, structural alignment with the developer, and a position that strengthens as the platform scales," said Michael K. Handley, Chief Executive Officer of Valion Bio (搜索).
Technology Platform Capabilities
The BioScan-NMR (搜索) platform represents a significant advancement in NMR technology, designed for rapid, label-free phenotyping of live cells and micro-sized biological samples. Unlike conventional NMR instrumentation, the system delivers molecular-level diagnostic information from small sample volumes in minutes without requiring cryogenics, dedicated infrastructure, or specialized personnel.
LarmorBio (搜索), founded as a Massachusetts Institute of Technology (MIT) spin-off, developed the platform to support applications across bioprocessing, cell and gene therapy development, and clinical diagnostics. The technology addresses key limitations of traditional NMR systems that have historically restricted their use in routine diagnostic applications.
Commercial and Operational Impact
The San Antonio installation is expected to anchor Velocity Bioworks (搜索)' advanced diagnostics service offering and serve as the demonstration and validation site for LarmorBio (搜索)'s broader commercial pipeline. Handley noted that "hosting the first commercial installation gives Velocity Bioworks a defined role in the validation and commercialization of a next-generation NMR platform, and supports an advanced diagnostics service offering that we believe will benefit the biomanufacturing of programs both our internal pipeline and our third-party CDMO clients."
The reference site role provides Velocity Bioworks (搜索) with first-mover access to the platform while giving LarmorBio (搜索) a high-visibility commercial proof point as it engages institutional capital and prospective customers. This arrangement positions both companies to benefit from the platform's validation and market development.
Company Background
Valion Bio (搜索), formerly Tivic Health Systems, Inc., is developing Entolimod, a TLR5 (搜索) agonist, for Acute Radiation Syndrome (搜索) (ARS), oncology supportive care, and longevity indications. Entolimod for ARS has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. The company is also advancing Entolasta (搜索), a next-generation TLR5 agonist designed for potential broader therapeutic applications.
Velocity Bioworks (搜索) operates as a full-service contract development and manufacturing organization (CDMO) headquartered in San Antonio, Texas, providing biomanufacturing, process development, and advanced analytics services to biotechnology and biopharmaceutical clients while serving as the manufacturing engine for Valion Bio (搜索)'s internal drug development pipeline.